FOUNDER

Mendy Lebowitz
Founder CardioSight
MD/PhD candidate in Biomedical Engineering at Emory University and Georgia Tech. Mendy is building CardioSight on the thesis that routine imaging can become a scalable platform for earlier detection and prevention of cardiovascular disease. The team has trained and validated its models on more than 75,000 CT scans across multiple imaging cohorts, with external validation in VA and NLST datasets. During the RightShift Accelerator he completed 60 customer discovery interviews, working from The Hatchery and HSRB II alongside a four-person team.
Former healthcare executive with deep domain expertise in women’s health. Strong product-market validation through clinical partnerships and user research.

The scan has already been taken

Cardiovascular disease is still identified too late, while the imaging that could have flagged it sits unread for that purpose. CardioSight reads cardiometabolic fat depots throughout the chest from CT scans that are already part of clinical care, and converts them into a long-term risk signal for heart attack, stroke, heart failure, and death. Because the input is imaging that already exists, adoption requires no new equipment, no additional radiation exposure, and no workflow redesign for the health system — the deployment barrier that usually stalls diagnostic AI.

INVESTMENT HIGHLIGHTS

Revenue Status
Pre-Revenue
Accelerators
RightShift, Emory Hatchery
Founder Solution Fit
[TBC]
Funded By
[TBC]

PRODUCT

Product phase

Stage
ETP / MVP
User Testing
60 discovery interviews
Design Partners
1
Waitlist
5
Product BG

Traction and Validation

75,000+
Models have been trained and validated across multiple imaging cohorts, with external validation performed on VA and NLST datasets.
60
Completed during the 10-week accelerator, alongside a validated problem statement, a defined ICP, a prioritized roadmap, a financial model, and an investor-ready deck — none of which existed at Week 1.
NO EXTRA STEPS
CardioSight runs on scans that are already being performed, so adoption requires no additional imaging, no added radiation, and no change to how clinicians work.

Platform Highlights

01
Runs on CT scans already performed in routine clinical care
02
Analyzes cardiometabolic fat depots throughout the chest
03
Predicts long-term risk of heart attack, stroke, heart failure, and death
04
No change to existing clinical workflow
05
Externally validated on VA and NLST imaging cohorts
06
No additional imaging and no added radiation exposure